This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chisamore, M. J. Articles by Tonetti, D. A. Search for Related Content PubMed PubMed Citation Articles by Chisamore, M. J. Articles by Tonetti, D. A.

Novel Antitumor Effect of Estradiol in Athymic Mice Injected with a T47D Breast Cancer Cell Line Overexpressing Protein Kinase C¹

Robert H. Lurie Comprehensive Cancer Center [M. J. C., Y. A., V. C. J., D. A. T.], and the Department of Surgery [D. J. B.], Northwestern University Medical School, Chicago, Illinois 60611

Purpose: Resistance to tamoxifen (TAM) represents a significant challenge to the management of breast cancer. We previously reported that the estrogen receptor (ER)-negative hormone-independent T47D:C42 cell line has both elevated protein kinase C (PKC) protein expression and basal activator protein-1 activity compared with the parental ER+ (hormone-dependent) T47D:A18 cell line. Stable transfection of PKC to the T47D:A18 breast cancer cell line results in increased basal activator protein-1 activity, reduced ER function, increased proliferation rate, and hormone-independent growth (Tonetti et al., Br. J. Cancer, 83: 782–791, 2000). In this report, we further characterize the role of PKC overexpression in vivo to elucidate a possible molecular mechanism of tamoxifen resistance.

Experimental Design: To determine whether the T47D:A18/PKC cell line would produce hormone-independent tumors in athymic mice, we injected T47D:A18, T47D:A18/neo, or the T47D:A18/PKC20 cell clones bilaterally into the mammary fat pads of athymic mice. Tumor growth was evaluated following treatment with estradiol (E2), TAM, and the pure antiestrogen, ICI 182,780.

Results: Mice receiving either T47D:A18 or T47D:A18/neo cells produced tumors that grew in response to E2 treatment, whereas the untreated control and TAM-treated groups showed no tumor growth. Interestingly, mice receiving the T47D:A18/PKC20 clone produced tumors in both the control and TAM groups, whereas tumor growth was inhibited in mice treated with E2. PKC was also overexpressed in an MCF-7 tumor model that also exhibited TAM-stimulated and E2-induced regression.

Conclusions: These results suggest that overexpression of PKC in breast tumors results in hormone-independent tumor growth that cannot be inhibited by TAM treatment. Furthermore, the finding that E2 has an antitumor effect on breast tumors overexpressing PKC is a novel observation that may have important therapeutic implications.

This article has been cited by other articles:

				C. Lanari, C. A Lamb, V. T Fabris, L. A Helguero, R. Soldati, M. C. Bottino, S. Giulianelli, J. P. Cerliani, V. Wargon, and A. Molinolo The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer Endocr. Relat. Cancer, June 1, 2009; 16(2): 333 - 350. [Abstract] [Full Text] [PDF]

				Y. Zhang, H. Zhao, S. Asztalos, M. Chisamore, Y. Sitabkhan, and D. A. Tonetti Estradiol-Induced Regression in T47D:A18/PKC{alpha} Tumors Requires the Estrogen Receptor and Interaction with the Extracellular Matrix Mol. Cancer Res., April 1, 2009; 7(4): 498 - 510. [Abstract] [Full Text] [PDF]

				X. Lin, Y. Yu, H. Zhao, Y. Zhang, J. Manela, and D. A. Tonetti Overexpression of PKC{alpha} is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model Carcinogenesis, August 1, 2006; 27(8): 1538 - 1546. [Abstract] [Full Text] [PDF]

				S. Glaros, N. Atanaskova, C. Zhao, D. F. Skafar, and K. B. Reddy Activation Function-1 Domain of Estrogen Receptor Regulates the Agonistic and Antagonistic Actions of Tamoxifen Mol. Endocrinol., May 1, 2006; 20(5): 996 - 1008. [Abstract] [Full Text] [PDF]

				Y Zhou, S Eppenberger-Castori, U Eppenberger, and C C Benz The NF{kappa}B pathway and endocrine-resistant breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S37 - S46. [Abstract] [Full Text] [PDF]

				S. I. Vanzulli, R. Soldati, R. Meiss, L. Colombo, A. A. Molinolo, and C. Lanari Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression Carcinogenesis, June 1, 2005; 26(6): 1055 - 1063. [Abstract] [Full Text] [PDF]

				R I Nicholson, C Staka, F Boyns, I R Hutcheson, and J M W Gee Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy Endocr. Relat. Cancer, December 1, 2004; 11(4): 623 - 641. [Abstract] [Full Text] [PDF]

				C. Osipo, H. Liu, K. Meeke, and V. C. Jordan The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death Experimental Biology and Medicine, September 1, 2004; 229(8): 722 - 731. [Abstract] [Full Text] [PDF]

				J. Spychala, E. Lazarowski, A. Ostapkowicz, L. H. Ayscue, A. Jin, and B. S. Mitchell Role of Estrogen Receptor in the Regulation of Ecto-5'-Nucleotidase and Adenosine in Breast Cancer Clin. Cancer Res., January 15, 2004; 10(2): 708 - 717. [Abstract] [Full Text] [PDF]

				H. Liu, E.-S. Lee, C. Gajdos, S. T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, et al. Apoptotic Action of 17{beta}-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo J Natl Cancer Inst, November 5, 2003; 95(21): 1586 - 1597. [Abstract] [Full Text] [PDF]

				J. Faridi, L. Wang, G. Endemann, and R. A. Roth Expression of Constitutively Active Akt-3 in MCF-7 Breast Cancer Cells Reverses the Estrogen and Tamoxifen Responsivity of these Cells in Vivo Clin. Cancer Res., August 1, 2003; 9(8): 2933 - 2939. [Abstract] [Full Text] [PDF]

				V. C. Jordan, H. Liu, and R. Dardes Re: Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17{beta}-Estradiol and The Two Faces of Janus: Sex Steroids as Mediators of Both Cell Proliferation and Cell Death J Natl Cancer Inst, August 7, 2002; 94(15): 1173 - 1173. [Full Text] [PDF]